Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ajman Government Media Office hosts Foreign Affairs Undersecretary at THE SIGNAL with a clear message: ‘The UAE does not seek the signal – it creates it’

    November 22, 2026

    Humaid bin Ammar attends day two of Ajman Media Forum 2026 and honours participants and partners

    November 22, 2026

    Ajman Government Media Office’s THE SIGNAL forum features Saeed Al Eter on how public trust and a successful development model underpin UAE soft power in times of crisis

    November 22, 2026
    Facebook X (Twitter) Instagram
    UAE IndependentUAE Independent
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • More
      • Sports
      • Technology
      • Travel
    UAE IndependentUAE Independent
    Home » VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
    ACCESS Newswire

    VisiRose Introduces Revolutionary Therapy for Severe Eye Infections

    December 10, 2024
    Facebook Twitter Pinterest LinkedIn Tumblr Email

    Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals

    KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine’s Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus’s pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI’s light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.

    RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico.

    “RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision,” said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.

    Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, “VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide.”

    “VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care,” said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.

    Dominic Rodrigues, Acting CEO of VisiRose added, “RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition.”

    In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.

    About VisiRose
    VisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine’s Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center’s innovative ocular research using Provectus’s bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.

    About Bascom Palmer Eye Institute
    The Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.

    About Provectus Biopharmaceuticals
    Provectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company’s lead molecule is named Rose Bengal Sodium. Provectus’s drug platform includes:

    • Clinical development programs in oncology, dermatology, and ophthalmology,
    • In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, and
    • In vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.

    Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.

    For Media Inquiries:
    VisiRose, Inc.
    E: contact@visirose.com
    W: visirose.com

    Contact:
    VisiRose, Inc.
    Dominic Rodrigues
    Acting Chief Executive Officer
    E: rodrigues@visirose.com

    SOURCE: VisiRose

    View the original press release on accesswire.com

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    American Businessman Mark Eric Williams Vindicated in Six-Year, US$150 Million-Plus Litigation Brought by Kuwaiti State Entities

    November 20, 2026

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Securitas Healthcare Introduces a New Era of RTLS Built for the Future of Healthcare Operations

    November 10, 2026
    Latest News

    Guinea declares mpox outbreak over after 42 days without cases

    Health November 21, 2026

    Guinea has declared an end to its mpox outbreak after two full incubation periods passed with no new active cases or chains of transmission. The government made the announcement on Thursday, November 19. Health Minister Khaite Sall said in an

    WFP seeks $12.1 billion to feed 91 million people in 2027

    November 21, 2026

    South Korea’s exports pass $1 trillion for the first time

    November 21, 2026

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026
    © 2026 UAE Independent | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.